MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 575533 | Name: Fludarabine diphosphate

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Fludarabine diphosphate is the phosphate salt of a fluorinated nucleotide antimetabolite analog of the antiviral agent vidarabine (ara-A) with antineoplastic activity.

Chemical Structure

Fludarabine diphosphate
Fludarabine diphosphate
CAS#107811-61-0 (diphosphate)

Theoretical Analysis

MedKoo Cat#: 575533

Name: Fludarabine diphosphate

CAS#: 107811-61-0 (diphosphate)

Chemical Formula: C10H14FN5O10P2

Exact Mass: 445.0200

Molecular Weight: 445.19

Elemental Analysis: C, 26.98; H, 3.17; F, 4.27; N, 15.73; O, 35.94; P, 13.91

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
21679-14-1 (free base) 75607-67-9 (phosphate) 107811-61-0 (diphosphate) 1169548-80-4 (F18)
Synonym
Fludarabine diphosphate
IUPAC/Chemical Name
2-Fluoro-9-(5-O-(hydroxy(phosphonooxy)phosphinyl)-beta-D-arabinofuranosyl)-9H-purin-6-amine
InChi Key
ZAHBDWMZWHJOLZ-FJFJXFQQSA-N
InChi Code
InChI=1S/C10H14FN5O10P2/c11-10-14-7(12)4-8(15-10)16(2-13-4)9-6(18)5(17)3(25-9)1-24-28(22,23)26-27(19,20)21/h2-3,5-6,9,17-18H,1H2,(H,22,23)(H2,12,14,15)(H2,19,20,21)/t3-,5-,6+,9-/m1/s1
SMILES Code
Nc1nc(F)nc2c1ncn2[C@@H]3O[C@H](COP(=O)(O)OP(=O)(O)O)[C@@H](O)[C@@H]3O
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 445.19 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Plosker GL, Figgitt DP. Oral fludarabine. Drugs. 2003;63(21):2317-23. doi: 10.2165/00003495-200363210-00004. PMID: 14524733. 2: Hood MA, Finley RS. Fludarabine: a review. DICP. 1991 May;25(5):518-24. doi: 10.1177/106002809102500512. PMID: 2068837. 3: Adkins JC, Peters DH, Markham A. Fludarabine. An update of its pharmacology and use in the treatment of haematological malignancies. Drugs. 1997 Jun;53(6):1005-37. doi: 10.2165/00003495-199753060-00007. PMID: 9179529. 4: Leblond V, Choquet S. Fludarabine in Waldenstrom's macroglobulinemia. Semin Oncol. 2003 Apr;30(2):239-42. doi: 10.1053/sonc.2003.50040. PMID: 12720144. 5: Lukenbill J, Kalaycio M. Fludarabine: a review of the clear benefits and potential harms. Leuk Res. 2013 Sep;37(9):986-94. doi: 10.1016/j.leukres.2013.05.004. Epub 2013 Jun 17. PMID: 23787174. 6: Lowe KL, Mackall CL, Norry E, Amado R, Jakobsen BK, Binder G. Fludarabine and neurotoxicity in engineered T-cell therapy. Gene Ther. 2018 Jun;25(3):176-191. doi: 10.1038/s41434-018-0019-6. Epub 2018 May 7. PMID: 29789639. 7: Elter T, Hallek M, Engert A. Fludarabine in chronic lymphocytic leukaemia. Expert Opin Pharmacother. 2006 Aug;7(12):1641-51. doi: 10.1517/14656566.7.12.1641. PMID: 16872267. 8: Anderson VR, Perry CM. Fludarabine: a review of its use in non-Hodgkin's lymphoma. Drugs. 2007;67(11):1633-55. doi: 10.2165/00003495-200767110-00008. PMID: 17661532. 9: Ross SR, McTavish D, Faulds D. Fludarabine. A review of its pharmacological properties and therapeutic potential in malignancy. Drugs. 1993 May;45(5):737-59. doi: 10.2165/00003495-199345050-00009. PMID: 7686467. 10: Shah N, Tam C, Seymour JF, Rule S. How applicable is fludarabine, cyclophosphamide and rituximab to the elderly? Leuk Lymphoma. 2015 Jun;56(6):1599-610. doi: 10.3109/10428194.2014.963083. Epub 2014 Nov 20. PMID: 25213181. 11: Tedeschi A, Alamos SM, Ricci F, Greco A, Morra E. Fludarabine-based combination therapies for Waldenström's macroglobulinemia. Clin Lymphoma Myeloma. 2009 Mar;9(1):67-70. doi: 10.3816/CLM.2009.n.017. PMID: 19362977. 12: Hiddemann W, Pott-Hoeck C. Fludarabine in the management of malignant lymphomas. Drugs. 1994;47 Suppl 6:50-6. doi: 10.2165/00003495-199400476-00008. PMID: 7525189. 13: Boogaerts MA. Oral fludarabine therapy in chronic lymphocytic leukemia-- increased convenience. Hematol J. 2004;5 Suppl 1:S31-7. doi: 10.1038/sj.thj.6200389. PMID: 15079151. 14: Voutsadakis IA. Fludarabine-induced eosinophilia: case report. Ann Hematol. 2002 May;81(5):292-3. doi: 10.1007/s00277-002-0457-4. Epub 2002 May 3. PMID: 12029541. 15: Lüftinger R, Zubarovskaya N, Galimard JE, Cseh A, Salzer E, Locatelli F, Algeri M, Yesilipek A, de la Fuente J, Isgrò A, Alseraihy A, Angelucci E, Smiers FJ, La La Nasa G, Zecca M, Fisgin T, Unal E, Kleinschmidt K, Peters C, Lankester A, Corbacioglu S; EBMT Pediatric Diseases, Inborn Errors Working Parties. Busulfan-fludarabine- or treosulfan-fludarabine-based myeloablative conditioning for children with thalassemia major. Ann Hematol. 2022 Mar;101(3):655-665. doi: 10.1007/s00277-021-04732-4. Epub 2022 Jan 9. PMID: 34999929. 16: Gandhi V. Fludarabine for treatment of adult acute myelogenous leukemia. Leuk Lymphoma. 1993;11 Suppl 2:7-13. doi: 10.3109/10428199309064255. PMID: 8124234. 17: Green S, Schultz L. Rational Alternatives to Fludarabine and Cyclophosphamide-Based Pre-CAR Lymphodepleting Regimens in the Pediatric and Young Adult B-ALL Setting. Curr Oncol Rep. 2023 Aug;25(8):841-846. doi: 10.1007/s11912-023-01404-6. Epub 2023 Apr 26. PMID: 37099243. 18: Tsimberidou AM, Keating MJ. Treatment of fludarabine-refractory chronic lymphocytic leukemia. Cancer. 2009 Jul 1;115(13):2824-36. doi: 10.1002/cncr.24329. PMID: 19402170. 19: Montillo M, Ricci F, Tedeschi A. Role of fludarabine in hematological malignancies. Expert Rev Anticancer Ther. 2006 Sep;6(9):1141-61. doi: 10.1586/14737140.6.9.1141. PMID: 17020450. 20: Gandhi V, Huang P, Plunkett W. Fludarabine inhibits DNA replication: a rationale for its use in the treatment of acute leukemias. Leuk Lymphoma. 1994;14 Suppl 2:3-9. doi: 10.3109/10428199409052689. PMID: 7881348.